拓扑替康单药治疗小细胞肺癌临床研究

Clinical Study on Topotecan as a Single Agent Therapy for Small Cell Lung Cancer

目的:探讨拓扑替康单药治疗小细胞肺癌(SCLC)的疗效及安全性。方法:初治和复治(SCLC)40例,可评价疗效35例,可评价不良反应40例。拓扑替康1.2mg·m-1·d-1,静脉滴注30分钟,每日1次连用5日,21天为1周期,2周期评价疗效,CR、PR者继续第3周期治疗。结果:在35例可评价疗效病例中,CR3例,PR13例,有效率45.7%,主要不良反应为骨髓抑制,非血液学毒性轻微,一般均可耐受。结论:拓扑替康是治疗SCLC的有效药物,初治疗效似优于复治,可作为SCLC一线或二线用药。

Objective:To evaluate the efficacy and safety profile of topotecan as a single a-gent chemotherapy for small cell lung cancer.(SCLC).Methods:Forty cases of previously treated and untreated SCLC patients were enrolled.Thirty-five patients were evaluated for effica-cy and all40cases were evaluated for safety.Topotecan was given as a30-min intravenous in-fusion at the dose of1.2mg /m2/day for5days and21days as a course.Efficacy was evaluated after two courses.A third course was given to CR and PR patients.Results:Thirty-five pa-tients went through the treatment schedule with3CR,13PR with a total effective rate of45.7%.Bone marrow suppression was the dominate side effect.Non-hematological side effects were slight and tolerable.Conclusion:Topotecan appears to be an effective first-line or sec-ond-line chemotherapeutic agent for SCLC and more effective for previously untreated patients.